Managing Lorlatinib's Unique Safety Profile: Dose Optimization and Practical Strategies for Long-Term Tolerability

This segment addresses one of the most practically important aspects of lorlatinib therapy — its distinct and manageable safety profile — and provides clinicians with actionable guidance on dose optimization strategies to support long-term treatment tolerability. With 34% of patients in the CROWN study requiring a dose reduction, and long-term efficacy shown to be preserved regardless of whether a dose reduction occurred, understanding how and when to adjust dosing is a critical skill for any oncologist prescribing this agent.

Dr. Shaw begins by walking through the constellation of side effects that make lorlatinib unique among ALK inhibitors. Hyperlipidemia — encompassing both elevated cholesterol and elevated triglycerides — is the most common adverse event, frequently reaching grade 3 or 4 severity, and notably emerges quickly, often within the first 2 weeks of therapy. Dr. Shaw shares her practice of checking lipid panels at the 2-week mark and initiating statin therapy promptly if levels have already risen above normal, as untreated hyperlipidemia will continue to climb.

Additional side effects discussed include fluid retention and edema, significant weight gain driven by increased appetite, peripheral neuropathy, and — perhaps most distinctively — neurocognitive and mood disturbances, which patients often describe as a “brain fog,” difficulty with word retrieval, or an intensification of emotional states. Drs. Lovly and Shaw emphasize the importance of counseling both patients and their caregivers about these effects before therapy begins, given their potential impact on daily functioning and quality of life. Importantly, all of these side effects are reversible and dose-dependent, making dose reduction a highly effective management tool rather than a treatment failure. Dr. Shaw shares her clinical approach of initiating lorlatinib at 75 mg rather than the standard 100 mg starting dose — particularly in older or frailer patients — to optimize tolerability from the outset. She also offers a practical prescribing tip: writing for 25 mg tablets rather than the 100 mg tablet allows seamless dose adjustments without requiring a new prescription, eliminating delays that could disrupt a patient's treatment continuity.